Status:
COMPLETED
Comparative Effectiveness of COPD Treatments
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
Up to 55 years
Brief Summary
To assess the effectiveness of maintenance treatment of Chronic obstructive pulmonary disease (COPD) with the combination of a long-acting bronchodilators (LABA and the long-acting muscarinic antagoni...
Eligibility Criteria
Inclusion
- New users of long-acting bronchodilators, LABA and tiotropium on the same date or of LABA and ICS, either as a fixed-dose combination or free combination, on the same date between January 2002 and December 2015
- Diagnosis of COPD and age ≥ 55 years
Exclusion
- Less than one year of medical history information prior to the date of combined treatment initiation (cohort entry)
- Asthma diagnosis
Key Trial Info
Start Date :
December 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2017
Estimated Enrollment :
3954 Patients enrolled
Trial Details
Trial ID
NCT03376295
Start Date
December 1 2017
End Date
December 31 2017
Last Update
July 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Clinical Epidemiology, McGill University
Montreal, Canada, H3T 1E2